<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03767855</url>
  </required_header>
  <id_info>
    <org_study_id>CY 6011</org_study_id>
    <nct_id>NCT03767855</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multi-Part, Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytokinetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytokinetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to:

        1. Learn about the safety of CK-3773274 after a single dose and multiple doses in healthy
           subjects.

        2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses.

        3. Find out how much CK-3773274 is in the blood after a single dose and multiple doses.

        4. Determine the effect of doses of CK-3773274 on the pumping function of the heart.

        5. Evaluate the effect of cytochrome genetic variants on how the body metabolizes
           CK-3773274.

        6. Evaluate the effect of a meal on how much CK-3773274 is in the blood in healthy adult
           subjects.

        7. Evaluate whether the amount of CK-3773274 in the blood is the similar for both the
           tablet and granules in capsule forms of the drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Actual">January 3, 2020</completion_date>
  <primary_completion_date type="Actual">January 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events and Safety Signals observed during single and multiple ascending doses of CK-3773274 administered orally to healthy adult subjects.</measure>
    <time_frame>SAD Cohorts: Day -1 - Day 10; CYP2D6 Cohort: Day -1 - Day - 24; MAD Cohorts: Day -1 - Day 27; Food Effect Cohort: Day -1 - Day 24; relative Bioavailability Cohort: Day -1 - Day 29</time_frame>
    <description>Subject incidence of AEs, SAEs, and reduced LVEF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of CK-3773274 after single and multiple ascending doses</measure>
    <time_frame>SAD Cohorts: Day 1; CYP2D6 Cohort: Day 1; MAD Cohorts: Day 14 or Day 17; Food Effect Cohort: Day 15; Relative Bioavailability Cohort: Day 15</time_frame>
    <description>Maximum concentration after dosing (Cmax) following single and multiple doses of CK-3773274 administered to healthy subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in absolute reduction in ejection fraction relative to baseline with doses of CK-3773274</measure>
    <time_frame>Time Frame for SAD Cohorts: Day -1 - Day 10; Time Frame for CYP2D6 Cohort: Day -1 - Day 24; Time Frame for MAD Cohorts: Day -1 - Day 27</time_frame>
    <description>Changes from baseline in LVEF as measured by echocardiography with doses of CK-3773274</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of CYP2D6 genetic variants on the PK of CK-3773274</measure>
    <time_frame>Day -1 - Day 24</time_frame>
    <description>Maximum concentration after dosing (Cmax) following a single dose administered to CYP2D6 poor metabolizers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of a meal on how much CK-3773274 is in the blood in healthy subjects</measure>
    <time_frame>Day -1 - Day 24</time_frame>
    <description>Maximum concentration after dosing (Cmax) following single and multiple doses of CK-3773274 administered to healthy subjects in fed and fasted states</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative bioavailability of CK-3773274 formulated as granules in capsule versus a tablet in healthy adult subjects</measure>
    <time_frame>Time Frame for Bioavailability Cohort: Day -1 - Day 29</time_frame>
    <description>PK parameters such as AUC calculated using plasma concentrations of CK-3773274</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Symptomatic Obstructive Hypertrophic Cardiomyopathy</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>CK-3773274 for SAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD Cohorts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CK-3773274 for MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD Cohorts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CK-3773274 for CYP2D6 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for CYP2D6 Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relative Bioavailability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-3773274 - Granules in Capsule</intervention_name>
    <description>CK-3773274 formulated as granules in capsule</description>
    <arm_group_label>CK-3773274 for CYP2D6 Cohort</arm_group_label>
    <arm_group_label>CK-3773274 for MAD Cohorts</arm_group_label>
    <arm_group_label>CK-3773274 for SAD Cohorts</arm_group_label>
    <arm_group_label>Food Effect</arm_group_label>
    <arm_group_label>Relative Bioavailability</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Granules in Capsule</intervention_name>
    <description>Placebo formulated as granules in capsule</description>
    <arm_group_label>Placebo for CYP2D6 Cohort</arm_group_label>
    <arm_group_label>Placebo for MAD Cohorts</arm_group_label>
    <arm_group_label>Placebo for SAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CK-3773274 - Tablets</intervention_name>
    <description>CK-3773274 formulated as tablets</description>
    <arm_group_label>Relative Bioavailability</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females (of non-childbearing potential) between 18 and 55 years of age,
             inclusive

          2. Body weight &gt; 55.0 kg and body mass index within 18.0 to 32.0 kg/m2, inclusive

          3. Normal cardiac structure and function, or if abnormalities are present, they are
             deemed not clinically significant

          4. Normal to high left ventricular ejection fraction.

          5. Normal electrocardiogram (ECG) or, if abnormalities are present, they are deemed not
             clinically significant

          6. Clinical laboratory findings within normal range

          7. Negative hepatitis panel (including hepatitis B surface antigen and hepatitis C
             antibody), and negative human immunodeficiency virus antibody screens

          8. Willing and able to refrain from strenuous exercise (eg, activity which could be
             expected to cause muscle soreness)

          9. For Arms 5 and 6 only: Subject is a CYP2D6 poor metabolizer

        Exclusion Criteria:

          1. History of any significant illness or disorder

          2. History of stomach or intestinal surgery or resection (appendectomy, hernia repair,
             and/or cholecystectomy will be allowed)

          3. A clinically significant illness within 4 weeks of Check-in

          4. Inability to swallow capsules or tablets

          5. History of or current substance abuse (drug or alcohol), known drug or alcohol
             dependence within the last 2 years prior to Screening, or positive test for drugs of
             abuse during the screening period

          6. Use of any tobacco-containing or nicotine-containing products within 3 months prior to
             Check-in

          7. Participation in any other investigational study drug trial in which receipt of an
             investigational study drug occurred within 30 days prior to Check-in

          8. Any blood donation within 60 days of dosing, plasma donation within 30 days of dosing,
             or receipt of blood products within 2 months prior to Check-in
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytokinetics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CK-3773274</keyword>
  <keyword>CK-274</keyword>
  <keyword>obstructive hypertrophic cardiomyopathy</keyword>
  <keyword>oHCM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

